Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 21

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 21
---
 |

<div align='center'>RISK FACTORS</div>

An investment in our common stock involves a high degree of risk. You should carefully consider the following risk factors and all the other information in this registration statement before you decide to buy our common stock. If any of the following risks related to our business actually occurs, our business, financial condition, operating results, and prospects would be adversely affected. The market price of our common stock could decline due to any of these risks and uncertainties related to our business, or related to an investment in our common stock, and you may lose part or all of your investment.Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Certain statements below are forward-looking statements.

Risks Related to this Offering

Sales of substantial amounts of our securities in the public market could depress the market price of our common stock.

Our common stock is listed for trading on the Nasdaq Capital Market. If our stockholders sell substantial amounts of our common stock in the public market, or the market perceives that such sales may occur, the market price of our securities could fall and we may be unable to sell our securities in the future.

Our securities may experience extreme price and volume fluctuations, which could lead to costly litigation for us and make an investment in us less appealing.

The market price of our common stock may fluctuate substantially due to a variety of factors, including:

| ● | the                                                                  
 status and results of our clinical trials for our product candidate; |

| ● | our                                                                                                                                
 ability to fund and complete our study and, if such study provides data supporting an FDA submission, our ability to apply for and 
 obtain clearance from the FDA;                                                                                                     |

| ● | our                                         
 ability to remain a going concern;          |
| ● | our ability to maintain our Nasdaq listing; |

| ● | our                          
 business strategy and plans; |

| ● | the                                                                           
 potential market for our product candidate, if approved for sale in the U.S.; |

| ● | new                                                                                                
 regulatory pronouncements and changes in regulatory guidelines and timing of regulatory approvals; |

| ● | general                                    
 and industry-specific economic conditions; |

| ● | variations                                                                                                                   
 in our quarterly financial and operating results, including the rate at which we incur negative cash flow in future periods; |

| ● | additions                              
 to or departures of our key personnel; |

| ● | changes                                                                                           
 in market valuations of other companies that operate in our business